← All stacks
Fat Loss

Tirzepatide + Cagrilintide

Also known as: Tirz + Cagri, Dual-Agonist + Amylin Stack

A weight-loss stack adding an amylin-based satiety signal on top of a dual GLP-1/GIP incretin agonist.

Components

How it's combined

Research framing combines tirzepatide (GLP-1/GIP dual agonist; FDA-approved for obesity as Zepbound) with cagrilintide (amylin analog) to add a separate fullness pathway tirzepatide does not directly hit. Notably, this specific pairing is compounded/experimental with no Phase 3 data; the validated amylin combination is CagriSema. Once-weekly subcutaneous in practice.

Available from vendors

PeptideChat is an independent research resource, not the seller. Links go to third-party vendors; products are sold strictly as research chemicals and are not intended for human consumption.

  • Independent research resource

    Not a seller — PeptideChat doesn't sell or ship products.

  • Research-use-only framing

    Content is educational, not a dosing recommendation.

  • Vendor links clearly disclosed

    Outbound links to third-party vendors are always labeled.

Research framing only. Stacks are described as they appear in research and biohacking literature. Nothing here is medical advice or a dosing protocol; these peptides are sold as research chemicals and are not approved for human use. Always consult a licensed healthcare provider.

PeptideChat is for educational and research purposes only. Nothing on this site constitutes medical advice. Peptides are sold as research chemicals only and are not intended for human use. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. PeptideChat is an independent educational resource — not a pharmacy, compounding, or 503A/503B outsourcing facility — and does not sell products or provide medical advice.